top of page
Pharma & Healthcare
Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.
One Pandemic, Two Bets, Opposite Outcomes
Moderna had no patent, no clinical data — just one peer-reviewed paper. J&J's vaccine used a far more mature, proven platform, and was pulled after $1.5B in losses. Why the safer-looking bet doesn't always win.
Jun 21
AI in Pharma's Quiet Wins: Clinical Trials and Manufacturing
AI drug discovery has one validated success and zero FDA approvals so far — while AI in trial design already has formal regulatory qualification from both the EMA and FDA. The most-hyped application in pharma AI isn't the one furthest along.
Jun 14
AI in Pharma: Separating Proven Results from Promising Platforms
AlphaFold won a Nobel Prize, but its own drug pipeline hasn't dosed a single patient. Meanwhile, a 21-day AI-designed molecule just posted real Phase IIa results in Nature Medicine. A clear-eyed look at what's proven versus still promised.
Jun 14
Cell and Gene Therapy Is Not Dead —It Is Being Rebuilt From the Ground Up
Cell and gene therapy generated over $14B in 2024, yet pharma spent $10B+ acquiring pre-commercial companies in just seven months. The "CGT is dead" narrative confuses a broken pricing model with failed science — the biology already works.
Jun 1
Who Funds Science-Driven Companies — and Who Actually Does the Science
Investment banks can't predict whether a drug will work — 50-70% of Phase 2 drugs fail before Phase 3, yet banks price pre-Phase 3 biotech IPOs on a 16-20 week timeline anyway. VC, IB, and PE each play a genuinely different role — only one is actually built to judge the science.
Jun 1
Why Private Equity Doesn’t Need to Understand the Science — And What That Means for You
A PE-owned nursing home chain study found a 10% rise in resident mortality — over 20,000 additional deaths — while financial metrics kept improving. Why private equity can be excellent at what it does and still be structurally unable to catch a scientific inflection before it's too late.
May 30
U.S.–China Biotech & Life Sciences Sector Analysis
Illumina lost 27% of its China revenue in one quarter after being blacklisted — retaliation for lobbying against its own top competitor, BGI. The company's CEO was the only life sciences executive in Trump's May 2026 Beijing delegation, while Pfizer and Eli Lilly stayed away, already deep in $50 billion of licensing deals that needed no summit at all.
May 21
Investment Scenario Analysis: Eli Lilly (LLY) and Summit Therapeutics (SMMT) Benchmarked Against the S&P 500 Index
SMMT's 5-year bull case reaches 500-1000% — but carries a real scenario of losing nearly everything. LLY, despite an 800% run since 2019, now trades at 38x earnings with a base case barely ahead of the S&P 500. A side-by-side scenario analysis across three completely different risk profiles.
May 7
Tech vs. Pharma: Why Technology Leads S&P 500 Growth — And What It Means for Investors
A tech company's marginal cost of serving one more customer is fractions of a penny. A pharma company's cost scales with every pill manufactured, shipped, and monitored. That single structural difference explains more of the tech-pharma performance gap than any other factor — and it's not the whole story.
May 5
How to Research Pharma Companies Like an Analyst: A Complete Guide to Public Information Sources for Serious Pharmaceutical Investors
Institutional-quality pharma research requires no Bloomberg terminal — it requires knowing that FDA Medical Reviews, R&D Day slide decks, and ClinicalTrials.gov protocols exist, and reading them critically. A complete map of every public source serious pharma investors use, and a step-by-step research workflow you can apply to any company.
May 1
bottom of page